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ABSTRACT 
Development and comparison of  
warfarin dosing algorithms in stroke patients 
 
Sun-Mi Cho 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Kyung-A Lee) 
 
The genes for cytochrome P450 2C9 (CYP2C9) and vitamin k epoxide 
reductase complex subunit 1 (VKORC1) have been identified and studied 
as important genetic determinants of warfarin dosing. We developed 
warfarin algorithm for Korean patients with stroke and compared the 
accuracy of warfarin dose prediction algorithms based on the 
pharmacogenetics. 
A total of 95 patients on stable maintenance dose of warfarin were 
enrolled. Warfarin dosing algorithm was developed using multiple linear 
regression analysis. The performance of all the algorithms was 
characterized with coefficient of determination, determined by linear 
regression, and the mean of percent deviation predicted doses from the 
actual dose. In addition, we compared the performance of the algorithms 
using percentage of predicted dose falling within ±20% of clinically 
observed dose and dividing the patients into a low-dose group 
(≤3mg/day), an intermediate-dose group (3-7mg/day), and a high-dose 
group (≥7mg/day).  
A newly developed algorithm included the variables of age, body 
weight, and CYP2C9 and VKORC1 genotype. Our algorithm accounted 
for 46.5% of variation in stable warfarin doses. The predicted doses using 
algorithms derived from Anderson and this study showed the best 
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correlation with the actual maintenance doses. Our algorithm performed 
best in predicting dose within 20% of actual dose and intermediate-dose.  
Our warfarin dosing algorithm may be useful for Korean patients with 
stroke.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------- 
Key words: CYP2C9, Korean, stroke, VKORC1, warfarin  
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I. INTRODUCTION 
Warfarin, the most commonly used oral anticoagulant in the world, is 
indicated for the prevention and treatment of thromboembolic events in 
patients with deep vein thrombosis, pulmonary embolism, atrial 
fibrillation and prosthetic heart valves. It is administered as a racemic 
mixture of the R- and S-enantiomers of warfarin. S-warfarin is more 
active isomer and has a higher rate of therapeutic effect. These 
enantiomers are extensively metabolized by various cytochrome P450 
enzymes. R-warfarin is mainly metabolized by cytochrome P450 1A2 
(CYP1A2), CYP2C19 and CYP3A4, while S-warfarin is predominantly 
metabolized by CYP2C9.1 Both enantiomers affect the coagulation 
cascade by inhibiting the activity of vitamin K epoxide reductase 
complex 1 (VKORC1) and thus interfering with the activation of clotting 
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factors II, VII, IX and X.2,3 However, despite its considerable benefit, 
warfarin is less frequently prescribed than it should be,4 which is a result 
of a relatively high adverse event rate and the difficulty in managing the 
therapy.5-7 Common adverse drug events (ADEs) arising from warfarin 
treatment include major and minor bleeding and hemorrhagic stroke.8 
ADEs are also frequently due to insufficient therapy: ischemic stroke and 
venous thromboembolism.9 Warfarin, has narrow therapeutic index, 
shows not only large inter-individual variations in dose response but also 
intra-individual variation. Because patients’ clinical characteristics such 
as age, gender, body weight, concurrent medications, diet, co-morbidities 
and patient compliance level have shown to have large influence in 
warfarin dosing,10 frequently monitoring of its effect, as measured by the 
international normalized ratio (INR), is warranted.  
CYP2C9 and VKORC1 have been identified as important genetic 
determinants of warfarin dosing and have been studied. The most 
common CYP2C9 genotype among all ethnic is CYP2C9*1, found in 
about 80% of Caucasians11 and 93% of Korean.12 Lindh et al13 
demonstrated that carriers of CYP2C9*2 and CYP2C9*3 alleles require 
less warfarin dose than carriers of wild type CYP2C9*1 genotype. 
Different allelic frequency was also observed with the most common 
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single nucleotide polymorphisms (SNPs) in the VKORC1 gene, 1173C>T 
(rs9934438). Around 35% of Caucasian carry CC genotype, while only 
about 15% carry the TT genotype. However, most of the Korean showed 
TT genotype, but less than 1% carry CC genotype.14 Carriers of 1173CT 
and 1173CC genotype need 44% and 97% more warfarin dose than 
carriers of 1173TT genotype.15 The clinical algorithms for determining 
warfarin dose containing clinical characteristics and pharmacogenetics 
information of the patients have been developed for more proper warfarin 
dose prediction. These algorithms are not intended to replace INR 
monitoring, but to increase the accuracy and reduce trial and error 
approach in warfarin dosing. According to International Warfarin 
Pharmacogenetics Consortium (IWPC) study,16 the algorithms using 
clinical and genetic information increase the accuracy in dose prediction 
than a fixed-dose approach or algorithms derived from clinical 
information. In addition, those are useful especially in the patients who 
may be administered more or less than appropriate dose.16  
 Personalized dosing and INR monitoring is required, because response 
to warfarin is different according to indication and the state of the disease. 
Studies of warfarin dose assessment so far have looked at mainly targeted 
at valvular heart disease. Among the leading causes of death in Korea, 
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stroke is occupied in the second place. In order to prevent recurrence of 
this stroke, warfarin has been widely used. However, there were few 
studies about comparison of predictive power of warfarin dosing control 
based on pharmacogenetics. Therefore, this study reviewed prescribed 
dose and actual INR response in patients with stroke and compared the 
accuracy of 10 warfarin dose prediction algorithms based on the 
pharmacogenetics. In addition, warfarin dosing algorithm for Korean 
patients with stroke was developed to improve the quality of care for 
stroke patients. 
 
II. MATERIALS AND METHODS 
1. Study subjects 
A total of 111 patients undergoing warfarin treatment for prevention and 
treatment of stroke and requesting genotyping of CYP2C9 and VKORC1 
were recruited retrospectively at the neurology clinic at the Severance 
Hospital, Seoul, Korea. All study participants were enrolled between 
January 2009 and August 2014. Patients included were adults, whose 
warfarin dose requirement had remained constant for at least 3 previous 
clinic visits over a minimum period of 3 months, and with an INR of the 
prothrombin time within the range of 1.5 to 3.0.17 Sixteen patients were 
excluded from the study according to enrolment criteria. This study was 
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approved by the Institutional Review Board of the Yonsei University 
Severance Hospital, Seoul, Korea. Written informed consent for genetic 
analysis was obtained from the patients.  
2. Demographic and clinical data collection 
Data were collected from patients’ medical records. These data included 
demographic characteristics, comorbidities, the stable therapeutic dose of 
warfarin, the INR achieved with a stable warfarin dose, the use of 
concomitant medications, and the genotype of CYP2C9 and VKORC1. 
The interacting drugs, which were defined based on previously published 
literature, were also reviewed.18,19 
3. Genotyping 
Genomic DNA was extracted from EDTA whole blood samples with 
QIAamp DNA extraction kit (Qiagen, Hilden, Germany). For 
determination of the CYP2C9 genotype, the CYP2C9*3 (1075A>C; 
rs1057910) SNP is selected. For VKORC1 genotypes, the VKORC1 
1173C>T (rs 9934438) SNP is determined. PCR and direct sequencing 
were performed using primers designed in Primer3 software 
(http://Frodo.wi.mit.edu/cgi-bin/primer3/primer3). Purified PCR products 
were obtained using a QIAquick Gel Extraction Kit (Qiagen, Düsseldorf, 
Germany) and were sequenced using a Big Dye Terminator Cycle 
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Sequencing Ready Reaction Kit (AppliedBiosystems, Foster City, CA, 
USA). Sequences were analyzed using an ABI 3500dx system (Applied 
Biosystems). To detect any sequence variations, the sequences were 
compared to the reference sequences using Sequencher software (Gene 
Codes, Ann Arbor, MI, USA).  
4. Dosing algorithms 
A literature search was performed from Pubmed database, with the 
search terms warfarin, algorithm, polymorphism, CYP2C9 and VKORC1, 
to select warfarin dosing algorithms. Algorithms were included based on 
the following criteria; 1) Equations to predict maintenance warfarin dose. 
2) Only two SNPs consisting of VKORC1 1173G>T (or VKORC1 
-1639G>A and 2255C>T) and CYP2C9*2 and/or *3. 3) Published in 
English.  
Nine algorithms were selected from the literature that met our inclusion 
criteria. These are referred to as Sconce et al,20 Anderson et al,21 Gage et 
al,22 Wu et al,23 IWPC,16 Wadelius et al,24 Huang et al,25 Ohno et al,26 and 
Cho et al27 throughout this manuscript. The aforementioned algorithms 
included adult patients with atrial fibrillation, venous thromboembolic 
diseases, recent orthopedic surgery, valvular disease, and stroke. 
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5. Data analysis 
Stepwise multiple regression analysis was performed to develop new 
warfarin dosing algorithm and the results of univariate analysis were 
used to choice predictors for multivariate analysis. Comparison of 
warfarin doses between the different genotypes was performed using the 
Mann Whitney U-test. Predictive accuracy was assessed by comparing 
the dose predicted by the ten algorithms to actual dose which the patient 
was taking. Predicted dose was calculated using published equations, 
except Gage’s calculated by input on the website 
http://www.warfarindosing.org. A best fit trendline and correlation 
coefficient were determined by linear regression. In addition, the mean of 
percent deviation of predicted dose from the actual dose was used to 
evaluate the predictive accuracy of each algorithm. In addition, we 
compared the performance of the algorithms using percentage of 
predicted dose falling within ±20% of clinically observed dose 28 and 
dividing the patients into a low-dose group (≤3mg/day), an 
intermediate-dose group (3-7mg/day), and a high-dose group (≥
7mg/day).16 All statistical tests were performed with a p-value < 0.05 
significance. All analyses were performed using the Statistical Package 
for Social Science (SPSS18.0 SPSS science, Chicago, IL, USA). 
10 
 
III. RESULTS 
1. Characteristics of the study groups 
The characteristics of all 95 patients are listed in Table 1. This study 
included 95 patients with a mean age 64 years (SD, ±13.2) ranging from 
27 to 88 years, including 62 males (65%). The mean body weight was 
65.1kg (SD, ±10.5) and the mean BSA was 1.7 (SD, ±0.2). The mean 
stable warfarin dose was 3.75 mg/day (SD, ±1.43). Concurrent diseases 
associated with these patients included atrial fibrillation (62 patients, 
65.3%), hypertension (47 patients, 49.5%), diabetes mellitus (25 patients, 
26.3%), heart diseases including coronary arterial occlusive disease (13 
patients, 13.7%), heart failure (6 patients, 6.3%), and cardiac valvular 
disease (9 patients, 9.5%). A total of 41 (43.2%) patients were receiving 
comedications that could affect the anticoagulation effect of warfarin, 
including amiodarone, aspirin, antiplatelet drugs, statins, thyroid 
hormone, and verapamil.  
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Table 1. Characteristics of the study population      
Variables   n=95 
 
  
Men (%) 
  
62/33 (65%/35%) 
Mean age (SD) (range) years 63.7 (13.2) (27-88) 
Body weight (SD) (range) kg 65.1 (10.5) (44-90) 
Mean BSA (SD) (range) m2 1.7 (0.2) (1.3-2.1) 
Smoking patients (%) 
 
23/95 (24.2%) 
 
      
Concurrent disease (%) 
    
 Atrial fibrillation 
 
62/95 (65.3%) 
 
 Cancer 
  
1/95 (1.1%) 
 
 Cardiac valvular disease 9/95 (9.5%) 
 
 CHF*/Cardiomyopathy 
 
6/95 (6.3%) 
 
 CAOD† 
  
13/95 (13.7%) 
 
 Diabetes mellitus 
 
25/95 (26.3%) 
 
 Hypertension 
 
47/95 (49.5%) 
 
 Hyperthyroidism 
 
2/95 (2.1%) 
 
 Hypothyroidism 
 
1/95 (1.1%) 
 
      Comedications 
    
 Amiodarone 
 
3/95 (3.2%) 
 
 Aspirin 
  
35/95 (36.8%) 
 
 Antiplatelet drug 
 
12/95 (12.6%) 
 
 Statins 
  
73/95 (76.8%) 
 
 Thyroid hormone 
 
1/95 (1.1%) 
 
 Verapamil   24/95 (25.3%)   
*CHF: Congestive heart failure 
†CAOD: Coronary arterial occlusive disease 
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2. Effects of genotype on stable dose of warfarin 
Table 2 showed the daily warfarin dose of different genotypes. For 
CYP2C9, 91 patients (95.8%) were identified to be homozygous for 
CYP2C9*1, and 4 patients (4.2%) were heterozygous for CYP2C9*3. The 
frequency of the VKORC1 1173TT genotype was 83.2% and that of 
1173CT genotype was 16.8%. In our study, no patients with homozygous 
CYP2C9*3/*3 and VKORC1 1173CC genotypes were identified. The 
stable warfarin doses for patients with VKORC1 CT genotype (4.6 ± 1.9 
mg/day) were significantly higher than that of TT type (3.6 ± 1.2 
mg/day). However, the difference in the stable warfarin doses between 
patients with homozygous for CYP2C9*1 (3.8 ± 1.4 mg/day) and 
heterozygous for CYP2C9*3 (2.6 ± 0.5 mg/day) was not significant.  
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Table 2. Effects of VKORC1 1173C>T and CYP2C9 genotypes on warfarin 
stable dose 
Genotype n warfarin dose (mg/day) p-value  
VKORC1 1173 
    
CC 0 
    
CT 16 4.6 ± 1.9  
 
< 0.05 
 
TT 79 3.6 ± 1.2  
   
CYP2C9*3 
    
*1/*1 91 3.8 ± 1.4  
 
0.073 
 
*1/*3 4 2.6 ± 0.5 
   
*3/*3 0       
 
3. Establishment of Dosing Algorithm 
For multiple linear regression analysis, 4 variables including age, 
bodyweight, CYP2C9*3 and VKORC1 1173 genotypes were selected 
(R2=0.465, Table 3). We established the warfarin dosing formula with 
following equation: maintenance dose = exp {1.896 - 0.016(age) + 
0.005(body weight) – 0.275(CYP2C9 genotype) + 0.318(VKORC1 
genotype)}. It was coded as 1 in the case of the presence of the CYP2C9 
variant, or the presence of the VKORC1 1173 C allele.  
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Table 3. Contribution of individual variables to the algorithm 
 
Variables  R (R2adj)  Slope (beta)  Standard Error  p-value  
All  0.699 (0.465)        
Age  0.606 (0.360)  -0.016 0.002 < 0.001  
Body weight  0.002 (0.004)  0.005 0.003 0.074 
CYP2C9 
genotypes 0.015 (0.012)  -0.275 0.14 0.053 
VKORC1 1173 
genotypes 0.076 (0.097)  0.318 0.076 < 0.001  
R2adj: R2 adjusted. 
 
4. Comparison of Dosing Algorithms 
A comparison of the ten algorithms for determining warfarin 
maintenance dosing is shown in Table 4. Most algorithms that evaluated, 
including the dosing algorithm derived from this study, had a good 
correlation. However, the algorithms by Gage et al,22 Wu et al,23 and 
Huang et al25 showed poor correlation. Algorithms from this study, 
Sconce et al,20 Anderson et al,21 and Ohno et al26 produce similar 
accuracy with mean deviation ranging from -10.8 to 3.9. These 
algorithms were selected based on their correlation coefficient (r > 0.6) 
and the mean deviation from the actual dose (mean deviation about 10%) 
for further analysis. The does which was predicted by using the algorithm 
from this study was more accurate in telling whether it falls within ±
20% of clinically observed dose (Table 5), while other algorithms show 
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similar accuracy among them and less accuracy to the algorithm above.  
Algorithms by Sconce et al,20 and Ohno et al26 tend to underestimate in 
about 40% of cases. In addition, the accuracy of this study was better 
than others for patients who need intermediate-dose group (Table 6). For 
patients who need less than 3 mg/day, algorithm by Ohno was well 
performed. However, for patients who required more than 7 mg/day, all 
algorithms performed poorly, with underestimation for all patients.  
Table 4. Comparison of the warfarin dosing algorithms 
Algorithm  R  R2 (R2adj)  Mean Deviation %  Regression Equation  
This study  0.684 0.468 (0.462)  2.8 y = 1.034x + 0.028  
Gage et al 0.55 0.303 (0.295)  -3.6 y = 0.686x + 1.516  
Sconce et al 0.613 0.376 (0.370)  -10.3 y = 0.952x + 0.753  
Wu et al 0.398 0.159 (0.150)  46.9 y = 0.673x + 0.430  
Anderson et al 0.68 0.463 (0.457)  3.9 y = 1.589x - 1.875  
Ohno et al 0.676 0.458 (0.452)  -10.8 y = 1.648x - 1.293  
Huang et al 0.464 0.215 (0.207)  -17.1 y = 0.958x + 1.042  
Wadelius et al  0.621 0.386 (0.379)  49.9 y = 1.082x - 1.743  
IWPC  0.673 0.453 (0.447)  -20.2 y = 1.421x - 0.198  
Cho et al 0.642 0.412 (0.406)  -54.9 y = 0.080x + 1.212  
R2adj: R2 adjusted. 
 
Table 5. Percentage of patients with an ideal, underestimated, or 
overestimated dose of warfarin as estimated by each algorithm 
Algorithm Ideal dose (%) Underestimation (%) Overestimation (%)  
This study 53.7 21.1 25.3 
Anderson et al 48.4 21.1 30.5 
Sconce et al 45.3 40 14.7 
Ohno et al 44.2 43.2 12.6 
Ideal dose: predicted dose falling within ±20% of clinically observed dose 
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Table 6. Sensitivity analysis with low-, intermediate-, and high- dose patient 
groups  
Algorithm  Subgroups based on the warfarin dose  
≤ 3 mg/d (n = 47)  > 3, < 7 mg/d (n = 45)  ≥ 7 mg/d (n = 3)  
This study 44.7 64.4 0 
Anderson et al  40.4 60 0 
Sconce et al 51.1 42.2 0 
Ohno et al 61.7 28.9 0 
 
IV. DISCUSSION 
Warfarin, the first human anticoagulant, is the most commonly 
prescribed oral anticoagulant in the world. Warfarin exerts its 
anticoagulant effect by inhibiting the activity of VKORC1 and thus 
interfering with the activation of vitamin K-dependent clotting factors II, 
VII, IX and X.2,3 Warfarin is underutilized for stroke prevention. The 
Agency for Healthcare Policy and Research noted that physicians avoid 
to prescribe warfarin, because they are not familiar with techniques for 
administrating the drug safely and fear bleeding complication.29 Warfarin 
therapy is challenging, since warfarin has narrow therapeutic index. In 
addition, it shows not only large inter-individual variations in dose 
response but also intra-individual variation. Because patients’ clinical 
characteristics such as age, gender, body weight, concurrent medications, 
diet, co-morbidities and patient compliance level largely influence in 
warfarin dosing,10 frequently monitoring of its effect, as measured by the 
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INR, is warranted.  
Since CYP2C9 and VKORC1 have been identified and studied as 
important genetic determinants of warfarin dosing. Two prospective 
studies21,30 on genotype-guided warfarin dosing predicted more 
accurately, resulted in reduction of dosing changes, minor bleeding 
complication, and time to reach in the therapeutic range. Although 
numerous warfarin dosing algorithms have been developed, their 
indications for warfarin usage were heterogeneous. Until now, there is no 
consensus among pharmacogenetic-guided dosing algorithms.  
We developed an algorithm to provide a practical formula for Korean 
patients with stroke. The warfarin dosing algorithm reported in this study 
was developed on a homogeneous population and single disease 
indication for stroke, since warfarin have been underused for prevention 
of stroke29 and there are few studies about warfarin dosing algorithm 
focused on stroke patients. Because the distribution of warfarin dose was 
skewed, we created dosing algorithm for log transformation of doses, as 
evidenced by a mean percent deviation that was lower than that for both 
the raw doses and square root of doses. We analyzed whether ten selected 
dosing algorithms, including the algorithm derived from this study, could 
accurately predict warfarin dose in the study population. Algorithm from 
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this study demonstrated good correlation with actual dose, with 
coefficient of determination (R2) of 0.465. Algorithm derived from this 
study is consisted with four factors; age, body weight, and genotypes of 
CYP2C9 and VKORC1. While reduced incorporated factors are 
convenient for physicians to use, this algorithm performed better than 
Gage et al,22 Wu et al,23 and IWPC.16 Approximately 11% of the variance 
in warfarin dosing can be explained by genotypes. Because allele 
frequencies of VKORC1 and CYP2C9 were different from race, the R2 
values of these genes differ among studies.  
Anderson et al,21 Ohno et al,26 and Sconce et al20 also showed good 
linear relationship with actual dose and predicted dose. However, the R2 
indicate only the linearity of the association, the mean deviation from 
actual dose is a better measure of the algorithms performance. Although 
those three algorithms showed a good correlation with the actual dose in 
our study population, a better prediction of dosage was achieved by our 
model. 
The algorithm devised by Cho et al27 was the latest warfarin dosing 
algorithm for Korean patients with atrial fibrillation and the best model 
for prediction of daily maintenance dose from the validation study. This 
algorithm showed a good relationship between the actual dose and the 
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predicted warfarin dose in our study population as reported in the 
previous study. However, this algorithm was the worst performing 
algorithm by means of the mean deviation. The mean age, the strongest 
predictor of warfarin dose, was slightly older in cohort of Cho et al., 
although its significance is unclear. Because these two algorithms 
developed for two different single disease indication; atrial fibrillation 
and stroke, these patients may be differently influenced by environmental 
factors such as coadministered drugs and comorbidities. Atrial fibrillation 
was indeed the most common indication of warfarin usage in this study. 
Beside heart problems that are shown in the table.1, other sources of 
cardioembolism including patent foramen ovale and left atrial thrombus 
were identified. Likewise with reports from western countries,31 
cervicocephalic artery dissections were common causes of stroke in 
young patients under 45. Cho et al27 reported that statins influence with 
the daily dose of warfarin. Simvastatin, fluvastatin, and lovasatin 
potentiate warfarin’s effect.19,32 In our study, most patients were taking 
statins which do not affect the warfarin’s effect such as atorvastatin, 
pitavastatin, and rosuvastatin. There is no correlation between daily dose 
of warfarin and statin status regardless of types of statins. 
The algorithm derived from this study was less predictable among 
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patients who required high doses of warfarin (≥7 mg/day). As this study 
was a small retrospective analysis with only a few patients requiring high 
doses, the results may have been skewed because of the individual 
patients. About 3% of the patient could have complications due to 
underdose. Of the three outliers, two patients were VKORC1 CT 
genotype. The other was TT type and he was taking antituberculosis 
drugs. Rifampin decreases INR increase via induction of hepatic 
metabolism of warfarin.19,33 Removal of these three data points improve 
the correlation coefficient for our algorithm (R2=0.55). However, the 
sample size was too small to make conclusion about efficacy of the 
dosing algorithms in this population.  
In this study, we found 0 and 4% prevalence of CYP2C9*2 and 
CYP2C9*3, respectively, which compares with the report of Cho et al., 
who also found no CYP2C9*2 and an 8.5% prevalence of *3. For 
VKORC1, we found 83.2%, 17.8% and 0% prevalence of VKORC1 TT, 
CT, CC genotype, respectively, which compares with the report of Cho et 
al., who found 75.4%, 23.1% and 1.5%, respectively. Our data showed 
that the CYP2C9 and VKORC SNPs for Korean were in Hardy-Weinberg 
equilibrium.  
Our study has several limitations. First, we did not have sufficient data 
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to include potentially important factors such as vitamin K intake or 
compliance of administration even if we educated the patients when 
starting warfarin. However, the percentage of variability in warfarin 
dosing from our study is similar to that in other compared models, so the 
effect of these variables is probably small. Second, because we 
investigated only one VKORC1 SNPs, requiring us to impute missing 
genotype for evaluation some models. Therefore, we substituted missing 
genotype based on linkage disequilibrium, which is generally reliable.34 
However, it may cause an error that would lead to decrease of the 
accuracy of our model. Third, only 4% of the study population was 
younger than 40 year of age; so, it may need additional models for stroke 
patients with younger age, as age is important factor of prediction.  
In order to improve dosing algorithms further, additional study will be 
necessary to find new genes and SNPs contained with these genes that 
influence warfarin pharmacokinetics and pharmacodynamics. Although 
the incorporation of additional variables could improve predictive 
algorithm, the gains may be modest and probably do not justify the cost 
effectiveness and improvement of clinical outcome. In addition, studies 
about clinical utility of these pharmacogenetic-guided algorithms should 
be evaluated. 
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V. CONCLUSION 
In conclusion, we developed warfarin dose prediction algorithm for 
patients with stroke and it explained 47% of the variation in the daily 
maintenance warfarin dose. Further studies to elucidate clinical utility of 
genotype-guided dosing and find the additional genetic association are 
necessary.  
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ABSTRACT(IN KOREAN) 
뇌졸중 환자의 와파린 용량 예측을 위한 알고리즘의 개발과 
기존 알고리즘과의 비교 
 
<지도교수 이 경 아> 
 
연세대학교 대학원 의학과 
 
조 선 미 
 
와파린 용량 결정에 중요한 역할을 하는 유전자인 cytochrome 
P450 2C9 (CYP2C9)와 vitamin k epoxide reductase complex subunit 1 
(VKORC1)이 발견된 이후로 이에 관하여 많은 연구가 
진행되었다. 본 연구에서는 한국인 뇌졸중 환자군으로부터 
와파린 용량을 예측하는 알고리즘을 도출하고, 기존의 
약물유적학적 방법을 이용한 알고리즘과의 수행능을 
평가하였다.  
 안정적인 유지 용량을 복용하는 95명의 환자를 대상으로 
하였다. 와파린 용량 예측 알고리즘은 다중 선형 회귀 분석을 
이용하여 구하였다. 알고리즘의 평가는 선형 회귀로부터 도출한 
결정 계수, 실제용량과 예측용량의 퍼센트 편차의 평균(mean of 
percent deviation)을 사용하였다. 이에 더해, 실제 용량의 ±20%를 
이상적인 용량으로 정하여 이에 도달하는 백분율과 각기 다른 
용량에서의 예측의 정확성을 비교하였다.  
 나이, 몸무게, CYP2C9 와 VKORC1 유전자형을 변수로 하는 
알고리즘을 개발하였고 이는 와파린 용량의 약 47%의 설명력을 
가졌다. Anderson 등의 연구와 본 연구에서 도출된 알고리즘의 
예측 용량은 실제 용량과 가장 좋은 연관성을 보였다. 또한, 본 
연구에서 도출된 알고리즘은 이상적 용량예측과 와파린 중간 
용량군에서의 예측에 가장 우수하였다.  
 본 연구에서 개발된 와파린 용량 예측은 한국인 뇌졸중 
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환자에서 유용할 것으로 생각한다.  
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